World Investment Advisors Acquires 8,961 Shares of Medtronic PLC $MDT

World Investment Advisors raised its holdings in Medtronic PLC (NYSE:MDT) by 5.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 167,403 shares of the medical technology company’s stock after purchasing an additional 8,961 shares during the quarter. World Investment Advisors’ holdings in Medtronic were worth $15,700,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of MDT. Barclays PLC grew its stake in Medtronic by 104.6% in the 3rd quarter. Barclays PLC now owns 6,831,203 shares of the medical technology company’s stock valued at $650,604,000 after purchasing an additional 3,492,192 shares during the period. Schroder Investment Management Group grew its stake in Medtronic by 78.3% in the 3rd quarter. Schroder Investment Management Group now owns 7,529,849 shares of the medical technology company’s stock valued at $717,143,000 after purchasing an additional 3,307,211 shares during the period. Guinness Asset Management LTD bought a new position in Medtronic in the 3rd quarter valued at $275,556,000. Wellington Management Group LLP grew its stake in Medtronic by 35.3% in the 3rd quarter. Wellington Management Group LLP now owns 10,189,586 shares of the medical technology company’s stock valued at $970,456,000 after purchasing an additional 2,658,981 shares during the period. Finally, SG Americas Securities LLC grew its stake in Medtronic by 2,297.7% in the 4th quarter. SG Americas Securities LLC now owns 2,510,712 shares of the medical technology company’s stock valued at $241,179,000 after purchasing an additional 2,406,000 shares during the period. Institutional investors own 82.06% of the company’s stock.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Investors appear to be reacting favorably to relief from a long-running legal overhang after a False Claims Act case was dismissed, which removes a source of headline risk for Medtronic and could improve sentiment toward the stock. Medtronic shares climb as investors digest legal overhang relief and fresh cardiac-tech updates
• Positive Sentiment: Fresh updates on Medtronic’s cardiac rhythm management and broader device pipeline are reinforcing hopes for stronger product momentum, especially around newer ablation and diabetes-related offerings. Medtronic shares climb as investors digest legal overhang relief and fresh cardiac-tech updates
• Positive Sentiment: Orchestra BioMed said enrollment in the BACKBEAT pivotal trial is on track to finish by the end of Q3 2026, with data expected in Q2 2027 and a planned FDA filing afterward. Because Medtronic is the strategic collaborator, this supports a longer-term growth and pipeline narrative. Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027
• Neutral Sentiment: Medtronic also announced a California site closure as part of restructuring and portfolio consolidation in cardiovascular businesses. That may help efficiency over time, but it is more of an operational cleanup than an immediate stock catalyst. Medtronic to close California site amid restructuring
• Negative Sentiment: Medtronic has still faced recent pressure from broader healthcare-sector rotation and earlier reports of a stock decline, suggesting investors are balancing the positive legal and pipeline news against a still-soft technical backdrop. Medtronic (MDT) Stock Drops Despite Market Gains: Important Facts to Note

Wall Street Analyst Weigh In

A number of research analysts have issued reports on MDT shares. Truist Financial reduced their price objective on Medtronic from $103.00 to $95.00 and set a “hold” rating for the company in a research note on Wednesday, April 15th. UBS Group dropped their price target on Medtronic from $104.00 to $90.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 22nd. Argus dropped their price target on Medtronic from $125.00 to $115.00 and set a “buy” rating on the stock in a research report on Monday, April 6th. JPMorgan Chase & Co. dropped their price target on Medtronic from $105.00 to $100.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 18th. Finally, Piper Sandler dropped their price target on Medtronic from $105.00 to $91.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 1st. Fifteen investment analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $107.80.

Medtronic Stock Up 3.1%

Shares of NYSE MDT opened at $76.85 on Wednesday. Medtronic PLC has a one year low of $74.40 and a one year high of $106.33. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. The business’s fifty day moving average price is $85.98 and its 200-day moving average price is $94.01. The stock has a market capitalization of $98.66 billion, a PE ratio of 21.41, a P/E/G ratio of 1.77 and a beta of 0.62.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. The firm had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities research analysts anticipate that Medtronic PLC will post 5.57 EPS for the current year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, April 17th. Investors of record on Friday, March 27th were issued a dividend of $0.71 per share. The ex-dividend date of this dividend was Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a yield of 3.7%. Medtronic’s dividend payout ratio is 79.11%.

Insider Transactions at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the sale, the executive vice president owned 32,768 shares of the company’s stock, valued at approximately $3,201,761.28. This represents a 61.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.26% of the company’s stock.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).